Beyondspring Inc

詳細情報 Beyondspring Inc 企業名

BeyondSpring Inc. is a clinical-stage global biopharmaceutical company. The Company is focused on developing innovative therapies to improve clinical outcomes for patients with high unmet medical needs. The Company operates through two segments: the Plinabulin pipeline and Targeted Protein Degradation (TPD) platform. Plinabulin is being developed as a pipeline in a drug in various cancer indications as a direct anti-cancer agent and to prevent chemotherapy-induced neutropenia (CIN). Plinabulin is a small molecule derived from a natural compound found in marine microorganisms. It is a selective immunomodulating microtubule-binding agent (SIMBA), which may provide multiple therapeutic opportunities. The TPD platform is utilizing molecular glue technology to develop therapeutic agents and discover and develop new chemical entities for the debilitating diseases and disorders. The Company is also developing three small-molecule immune agents.

企業情報

企業コードBYSI

会社名Beyondspring Inc

上場日Mar 09, 2017

最高経営責任者「CEO」Dr. Lan Huang, Ph.D.

従業員数40

証券種類Ordinary Share

決算期末Mar 09

本社所在地100 Campus Drive, West Side, 4Th Floor

都市FLORHAM PARK

証券取引所NASDAQ Capital Market Consolidated

国United States of America

郵便番号07932

電話番号16465284184

ウェブサイトhttps://www.beyondspringpharma.com/en/

企業コードBYSI

上場日Mar 09, 2017

最高経営責任者「CEO」Dr. Lan Huang, Ph.D.

役員一覧

会社名

会社名/ポジション

ポジション

株式保有

変動額

Dr. Lan Huang, Ph.D.

Chairperson of the Board, Chief Executive Officer, Co-Founder

4.26M

--

Mr. Patrick (Pat) Fabbio

Independent Director

53.86K

+119.03%

Dr. Jiangwen (Jen) Majeti, Ph.D.

Independent Director

50.91K

--

Dr. June Lu, Ph.D.

Chief Scientific Officer

--

Mr. Sihai Xu

Director

--

Mr. Brendan P. Delaney

Independent Director

--

Mr. Matthew Kirkby

Independent Director

--

-100.00%

会社名

会社名/ポジション

ポジション

株式保有

変動額

Dr. Lan Huang, Ph.D.

Chairperson of the Board, Chief Executive Officer, Co-Founder

4.26M

--

Mr. Patrick (Pat) Fabbio

Independent Director

53.86K

+119.03%

Dr. Jiangwen (Jen) Majeti, Ph.D.

Independent Director

50.91K

--

Dr. June Lu, Ph.D.

Chief Scientific Officer

--

Mr. Sihai Xu

Director

--

Mr. Brendan P. Delaney

Independent Director

--

収益内訳

データなし

データなし

事業別

地域別

データなし

株主

更新時刻: Sat, Jul 19

株主統計

種類

株主統計

比率

Decheng Capital LLC

12.11%

Huang (Lan)

10.58%

Jia (Linqing)

4.43%

The Vanguard Group, Inc.

1.30%

BlackRock Institutional Trust Company, N.A.

0.29%

Other

71.30%

株主統計

比率

Decheng Capital LLC

12.11%

Huang (Lan)

10.58%

Jia (Linqing)

4.43%

The Vanguard Group, Inc.

1.30%

BlackRock Institutional Trust Company, N.A.

0.29%

Other

71.30%

種類

株主統計

比率

Individual Investor

15.26%

Venture Capital

12.11%

Investment Advisor

1.69%

Investment Advisor/Hedge Fund

0.35%

Hedge Fund

0.13%

Bank and Trust

0.09%

Research Firm

0.03%

Other

70.33%

機関投資家保有株

更新時刻: Tue, Jul 1

報告期間

機関投資家数

保有株式数

比率

変動額

2025Q2

62

11.96M

29.67%

-626.00K

2025Q1

65

11.44M

28.38%

-1.18M

2024Q4

71

11.41M

28.30%

-5.42M

2024Q3

73

15.85M

39.34%

-1.46M

2024Q2

85

16.08M

39.89%

-939.10K

2024Q1

128

16.18M

41.46%

-1.22M

2023Q4

143

15.76M

40.39%

-1.74M

2023Q3

172

17.23M

44.26%

-3.36M

2023Q2

182

17.28M

44.39%

-4.16M

2023Q1

198

17.53M

45.04%

-4.14M

詳細を見る

株主動向

会社名

保有株式数

比率

変動額

変動率

日付

Decheng Capital LLC

4.88M

12.11%

-75.49K

-1.52%

Mar 31, 2025

Huang (Lan)

4.26M

10.58%

--

Feb 28, 2025

Jia (Linqing)

1.78M

4.43%

+4.00

+0.00%

Feb 28, 2025

BlackRock Institutional Trust Company, N.A.

115.97K

0.29%

-1.09K

-0.93%

Mar 31, 2025

BlackRock Financial Management, Inc.

90.54K

0.22%

--

Mar 31, 2025

Fabbio (Patrick)

53.86K

0.13%

+29.27K

+119.03%

Feb 28, 2025

Majeti (Jiangwen)

50.91K

0.13%

--

Feb 28, 2025

UBS Switzerland AG

34.93K

0.09%

-17.48K

-33.35%

Mar 31, 2025

Tanaka Capital Management, Inc.

26.30K

0.07%

-3.18K

-10.78%

Mar 31, 2025

詳細を見る

2.190USD

Beyondspring Inc

2.190

概要

企業名

金融